Release Date: 2024-05-28

Alzheimer’s Disease and Obesity

Solmaz Susam (Author), Nevin Ilhan (Author)

Release Date: 2024-05-28

Research has highlighted the role of adipokines, signaling molecules secreted by adipose tissue, in both metabolic dysregulation associated with obesity and the neurodegenerative processes underlying AD. Key adipokines include leptin, which has neuroprotective effects, adiponectin, which has anti-inflammatory and insulin-sensitizing properties, and resistin, which is implicated in insulin resistance and may contribute to neuroinflammation and [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inAlzheimer’s Disease From Molecular Mechanisms to Clinical Practices
First Page259
Last Page274
DOIhttps://doi.org/10.69860/nobel.9786053359166.11
ISBN978-605-335-916-6 (PDF)
LanguageENG
Page Count16
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Research has highlighted the role of adipokines, signaling molecules secreted by adipose tissue, in both metabolic dysregulation associated with obesity and the neurodegenerative processes underlying AD. Key adipokines include leptin, which has neuroprotective effects, adiponectin, which has anti-inflammatory and insulin-sensitizing properties, and resistin, which is implicated in insulin resistance and may contribute to neuroinflammation and cognitive decline. Understanding the interplay between obesity, adipokines, and AD is crucial for identifying novel therapeutic strategies targeting both metabolic and cognitive impairments. This chapter aims to elucidate the relationship between AD and obesity, with a focus on selected adipokines that play pivotal roles in obesity-related pathophysiological mechanisms and neuroinflammation. Another critical pathological feature of AD is the formation of neurofibrillary tangles (NFTs), produced by hyperphosphorylated tau. In summary, The chapter shows the connections between obesity, adipokines, and AD highlights shared pathophysiological mechanisms.

Solmaz Susam (Author)
Adıyaman University
https://orcid.org/0000-0002-7503-2416
3Curriculum Vitae of Solmaz Susam Solmaz Susam graduated from Fırat University, Faculty of Science, Department of Chemistry. She earned her master’s and doctorate degrees from Fırat University, Faculty of Medicine, Department of Medical Biochemistry. Currently, she is employed as a doctoral faculty member at Adıyaman University, Department of Medical Biochemistry. Her academic journey and professional role focus on advancing the field of medical biochemistry through research and teaching. With a specialized expertise in medical biochemistry, she contributes to academic and scientific communities, aiming to enhance understanding and application of biochemistry in medical science.

Nevin Ilhan (Author)
Professor, Fırat University
https://orcid.org/0000-0002-0208-8929
3Prof. Dr. Nevin İlhan (MD, PhD) is a renowned specialist in medical biochemistry with a distinguished career in both clinical practice and academic research. She earned her medical degree from Dicle University and completed her PhD in Biochemistry at Fırat University. Currently, she serves as a professor at the Faculty of Medicine at Fırat University. With over 30 years of experience in the field, Prof. Dr. İlhan has made significant contributions to the understanding of metabolic disorders and biomarker discovery. She has published extensively in high-impact scientific journals and presented her findings at numerous international conferences. Her research focuses on the molecular mechanisms of disease and the development of novel diagnostic techniques. In addition to her research, Prof. Dr. İlhan is dedicated to teaching and mentoring medical school students and medical biochemistry specialists. She has supervised many graduate, doctoral and medical specialist students and helping to sharing their careers in medical biochemistry. Her expertise and commitment to excellence have earned her numerous awards and accolades from the scientific community.

  • World Health Organization. Obesity and Overweight. Available online at: https://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf. 2020.

  • El-Mallah C, Obeid O. Obesity and adiposity: the culprit of dietary protein efficacy.Clin Sci. 2020; 134:389-401.

  • Al-Kuraishy HM, Al-Gareeb AI, Alsayegh AA, Hakami ZH, Khamjan NA, Saad HM, et al.A potential link between visceral obesity and risk of Alzheimer’s disease. Neurochem Res. 2023; 48:745-766.

  • Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y.Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index.Am J Clin Nutr. 2000; 72:694-701.

  • Freedman DS, Sherry B. The validity of BMI as an indicator of body fatness and risk among children. Pediatrics. 2009; 124: 23-34.

  • Uranga RM, Keller JN. The complex interactions between obesity, metabolism and the brain. Front Neurosci. 2019; 13:443886.

  • Iadecola C.Vascular and metabolic factors in Alzheimer’s disease and related dementias: introduction.Springer. 2016; 36:151-154.

  • Shie F-S, Shiao Y-J, Yeh C-W, Lin C-H, Tzeng T-T, Hsu H-C, et al. Obesity and hepatic steatosis are associated with elevated serum amyloid beta in metabolically stressed APPswe/PS1dE9 mice.PloS one 2015; 10:e0134531.

  • Sparks DL, Scheff SW, Hunsaker III JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol.Exp Neuro. 1994; 126:88-94.

  • Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. Hypercholesterolemia accelerates Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7:321-331.

  • Bartos A, Fialová L, Švarcová J, Ripova Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J Neuroimmunol. 2012; 252:100-105.

  • Julien C, Tremblay C, Phivilay A, Berthiaume L, Émond V, Julien P, et al. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging. 2010; 31:1516-1531.

  • Gregor MF, Hotamisligil GS.Inflammatory mechanisms in obesity.Annu Rev Immuno. 2011; 29:415-445.

  • Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. Clin Invest. 2017; 127:1-4.

  • Appari M, Channon KM, McNeill E. Metabolic regulation of adipose tissue macrophage function in obesity and diabetes. J Antioxid Act. 2018; 29:297-312.

  • Artemniak-Wojtowicz D, Kucharska A, Pyrżak B. Obesity and chronic inflammation crosslinking. Cent Eur J Immunol. 2020; 45:461-468.

  • Monteiro R, Azevedo I.Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010; 2010:289645.

  • Castoldi A, Naffah de Souza C, Câmara NOS, Moraes-Vieira PM. The macrophage switch in obesity development.Front Immunol. 2016; 6:170492.

  • Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Immunol. 2020;10:505887.

  • García‐García I, Fernández‐Andújar M, Narváez M, García‐Casares N. Assessing adipokines as potential biomarkers of dementia, Alzheimer's disease, and mild cognitive impairment: A systematic review and meta‐analysis.Obes Rev. 2023; 24:e13573.

  • Ly M, Gary ZY, Mian A, Cramer A, Meysami S, Merrill DA, et al. Neuroinflammation: A Modifiable Pathway Linking Obesity, Alzheimer's Disease, and Depression.Am J Geriatr Psychiatry.2023; 31:853-866.

  • Flores-Cordero JA, Pérez-Pérez A, Jiménez-Cortegana C, Alba G, Flores-Barragán A, Sánchez-Margalet V.Obesity as a risk factor for dementia and Alzheimer’s disease: the role of leptin. Int J Mol Sci. 2022; 23:5202.

  • Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH.Peripheral cytokines and chemokines in Alzheimer’s disease.Dement Geriatr Cogn Disord. 2009; 28:281-287.

  • Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grubeck-Loebenstein B.Costimulatory effects of interferon-and interleukin-1 or tumor necrosis factor on the synthesis of A 1-40 and A 1-42 by human astrocytes.Neurobiol Dis. 2007; 7:682-689.

  • Bednarska-Makaruk M, Graban A, Wiśniewska A, Łojkowska W, Bochyńska A, Gugała-Iwaniuk M, et al.Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia.Biogerontology. 2017; 18:561-580.

  • Yekollu SK, Thomas R, O’Sullivan B. Targeting curcusomes to inflammatory dendritic cells inhibits NF-κB and improves insulin resistance in obese mice. Diabetes. 2011; 60:2928-2938.

  • Hasegawa Y, Saito T, Ogihara T, Ishigaki Y, Yamada T, Imai J, et al.Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans.Circulation. 2012; 125:1122-1133.

  • Kueck PJ, Morris JK, Stanford JA. Current Perspectives.Obesity and Neurodegeneration-Links and Risks. Degener Neurol Neuromuscul Dis. 2023; 13:111-129.

  • Wang C, Fan L, Khawaja RR, Liu B, Zhan L, Kodama L, et al.Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy.Nat Commun. 2022; 13:1969.

  • Sandhu M, Irfan HM, Shah SA, Ahmed M, Naz I, Akram M, et al.Friedelin attenuates neuronal dysfunction and memory impairment by inhibition of the activated JNK/NF-κB signalling pathway in scopolamine-induced mice model of neurodegeneration.Molecules. 2022; 27:4513.

  • Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017;1863(5):1037-1045.

  • Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease—a double-edged sword.Neuron. 2002; 35:419-432.

  • Bettcher BM, Kramer JH: Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.: Neurocase. 2013; 19:182-200.

  • Forny-Germano L, De Felice FG, Vieira MNdN.The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer’s disease.Front Neurosci. 2019; 12:430286.

  • Letra L, Santana I, Seiça R.Obesity as a risk factor for Alzheimer’s disease: the role of adipocytokines.Metab Brain Dis. 2014; 29:563-568.

  • Butterfield DA, Poon HF, Clair DS, Keller JN, Pierce WM, Klein JB, et a.Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease.Neurobiol Dis. 2006; 22:223-232.

  • Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BW.Is depression associated with increased oxidative stress? A systematic review and meta-analysis.Psychoneuroendocrinology. 2015; 51:164-175.

  • Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity.J Physiol Biochem .68:701-711,2012.

  • Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer’s disease-lessons from pathology. BMC Medicine. 2014; 12:1-12.

  • Charisis S, Lin H, Ray R, Joehanes R, Beiser AS, Levy D, et al.Obesity impacts the expression of Alzheimer's disease–related genes: The Framingham Heart Study.Alzheimers Dement. 2023; 19:3496-3505.

  • Hruby A, Hu FB: The epidemiology of obesity: a big picture. Pharmacoeconomics 2015; 33:673-689.

  • Sun Z, Wang Z-T, Sun F-R, Shen X-N, Xu W, Ma Y-H, et al. Late-life obesity is a protective factor for prodromal Alzheimer’s disease: a longitudinal study.Aging (Albany NY).2020; 12:2005-2017.

  • Gray SL, Anderson ML, Hubbard RA, LaCroix A, Crane PK, McCormick W, et al.Frailty and incident dementia. J Gerontol A Biol Sci Med Sci. 2013; 68:1083-1090.

  • Mooldijk SS, de Crom TO, Ikram MK, Ikram MA, Voortman T.Adiposity in the older population and the risk of dementia: The Rotterdam Study.Alzheimers Dement. 2023; 19:2047-2055.

  • Tracy AL, Jarrard LE, Davidson TL. The hippocampus and motivation revisited: appetite and activity.Behav Brain Res. 2001; 127:13-23.

  • Cova I, Clerici F, Rossi A, Cucumo V, Ghiretti R, Maggiore L, et al: Weight loss predicts progression of mild cognitive impairment to Alzheimer’s disease. PloS one. 2016; 11:e0151710,.

  • Lilamand M, Bouaziz-Amar E, Dumurgier J, Cognat E, Hourregue C, Mouton-Liger F, et al. Plasma leptin is associated with amyloid CSF biomarkers and Alzheimer’s disease diagnosis in cognitively impaired patients. J Gerontol A Biol Sci Med Sci.2023; 78:645-652.

  • Saha S, Hatch DJ, Hayden KM, Steffens DC, Potter GG. Appetite and weight loss symptoms in late-life depression predict dementia outcomes.Am J Geriatr Psychiatry. 2016; 24:870-878.

  • Huber K, Szerenos E, Lewandowski D, Toczylowski K, Sulik A.The Role of Adipokines in the Pathologies of the Central Nervous System.Int J Mol Sci. 2023; 24:14684.

  • Picó C, Palou M, Pomar CA, Rodríguez AM, Palou A. Leptin as a key regulator of the adipose organ. Rev Endocr Metab Disord. 2022; 23:13-30.

  • Sanborn V, Preis SR, Ang A, Devine S, Mez J, DeCarli C, et al.Association between leptin, cognition, and structural brain measures among “early” middle-aged adults: results from the Framingham Heart Study third generation cohort.J Alzheimer's Dis. 2020; 77:1279-1289.

  • Di Spiezio A, Sandin ES, Dore R, Müller-Fielitz H, Storck SE, Bernau M, et al. The LepR-mediated leptin transport across brain barriers controls food reward.Mol Metab. 2018; 8:13-22.

  • Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y.The blood–brain barrier: structure, regulation, and drug delivery.Signal Transduct Target Ther. 2023; 8:217.

  • Javed K, Reddy V, Lui F. Neuroanatomy, Choroid Plexus. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC. 2024.

  • Martínez-Sánchez N: There and back again: leptin actions in white adipose tissue. Int J Mol Sci. 2020; 21: 6039.

  • Cottrell EC, Mercer JG: Leptin receptors.: Handb Exp Pharmacol. 2012; 209:3-21.

  • Tošić I, Frank DA: STAT3 as a mediator of oncogenic cellular metabolism. Pathogenic and therapeutic implications. Neoplasia. 2021; 23:1167-1178.

  • Mejido DC, Peny JA, Vieira MN, Ferreira ST, De Felice FG.Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease.Neuropharmacology. 2020; 171:108115.

  • Arnoldussen IA, Kiliaan AJ, Gustafson DR: Obesity and dementia: adipokines interact with the brain.: Eur Neuropsychopharmacol. 2014; 24:1982-1999.

  • Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, Sánchez-Margalet V. Role of leptin in inflammation and vice versa.Int J Mol Sci. 2020; 21:5887.

  • Chen Y, Yu Y: Tau and neuroinflammation in Alzheimer’s disease: Interplay mechanisms and clinical translation. J Neuroinflammation. 2023; 20:165.

  • Mullins RJ, Diehl TC, Chia CW, Kapogiannis D: Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease. Front Aging Neurosci. 2017; 9:118.

  • De la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs. 2017; 77:47-65.

  • Li X-M, Yan H-J, Guo Y-S, Wang D. The role of leptin in central nervous system diseases.Neuroreport. 2016; 27:350-355.

  • Polito R, Di Meo I, Barbieri M, Daniele A, Paolisso G, Rizzo MR. Adiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review.Int J Mol Sci. 2020; 21:9255.

  • Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL, et al. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes. 2006; 55:141-147.

  • Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, et al.Adiponectin acts in the brain to decrease body weight.Nat Med. 2004; 10:524-529.

  • Neumeier M, Weigert J, Buettner R, Wanninger J, Schäffler A, Müller AM, et al.Detection of adiponectin in cerebrospinal fluid in humans. Am J Physiol Endocrinol Metab. 2007; 293:E965-E999.

  • Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM, et al.Adiponectin: Structure, physiological functions, role in diseases, and effects of nutrition.Nutrients. 2021; 13:1180.

  • Begum M, Choubey M, Tirumalasetty MB, Arbee S, Mohib MM, Wahiduzzaman M, et al.Adiponectin: a promising target for the treatment of diabetes and its complications.Life. 2023; 13:2213.

  • Fujishima Y, Maeda N, Matsuda K, Masuda S, Mori T, Fukuda S, et al. Adiponectin association with T-cadherin protects against neointima proliferation and atherosclerosis. Faseb J . 2017; 31:1571-1583.

  • Gamberi T, Magherini F, Modesti A, Fiaschi T. Adiponectin signaling pathways in liver diseases.Biomedicines. 2018; 6:52.

  • Choi HM, Doss HM, Kim KS.Multifaceted physiological roles of adiponectin in inflammation and diseases.Int J Mol Sci. 2020; 21:1219.

  • Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010; 464:1313-1319.

  • Zhao Z, Yan J, Huang L, Yang X.Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action.Biomed Pharmacother. 2024; 173:116373.

  • Kim MW, Abid Nb, Jo MH, Jo MG, Yoon GH, Kim MO. Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer’s disease-like pathologies.Sci Rep.2017; 27:12435.

  • Ali M, Wani SUD, Dey T, Sridhar SB, Qadrie ZL. A common molecular and cellular pathway in developing Alzheimer and cancer.Biochem Biophys Rep.2024; 37:101625.

  • Sun E, Motolani A, Campos L, Lu T. The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer's Disease.Int J Mol Sci. 2022; 23:8972.

  • Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT: Inflammation as a central mechanism in Alzheimer's disease.Alzheimer's Dement. 2018; 4:575-590.

  • Snow WM, Albensi BC. Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease.Front Mol Neurosci. 2016; 9:118.

  • Parimisetty A, Dorsemans A-C, Awada R, Ravanan P, Diotel N, Lefebvre d’Hellencourt C. Secret talk between adipose tissue and central nervous system via secreted factors—an emerging frontier in the neurodegenerative research. J Neuroinflammation. 2016; 13:1-13.

  • Grassi S, Mauri L, Prioni S, Cabitta L, Sonnino S, Prinetti A, et al.Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for brain diseases.Front Pharmacol. 2019; 10:807.

  • Jung Y, Lopez-Benitez J, Tognoni CM, Carreras I, Dedeoglu A.Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer’s disease.Brain Research. 2023; 1799:148171.

  • Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK: Resistin: A journey from metabolism to cancer.: Transl Oncol. 2021; 14:101178.

  • Kos K, Harte AL, da Silva NF, Tonchev A, Chaldakov G, James S, et a. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus.J Clin Endocrinol Metab. 2007; 92:1129-1136.

  • Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease.Br J Pharmacol.2012; 165:622-632.

  • Ahmad MA, Kareem O, Khushtar M, Akbar M, Haque MR, Iqubal A, et al.Neuroinflammation: a potential risk for dementia.Int J Mol Sci. 2012; 23:616.

  • Demirci S, Aynalı A, Demirci K, Demirci S, Arıdoğan BC. The serum levels of resistin and its relationship with other proinflammatory cytokines in patients with Alzheimer’s disease.Clin Psychopharmacol Neurosci. 2017;15 (1) :59-63.

  • Berlanga-Acosta J, Guillén-Nieto G, Rodríguez-Rodríguez N, Bringas-Vega ML, García-del-Barco-Herrera D, Berlanga-Saez JO, et al.Insulin resistance at the crossroad of Alzheimer disease pathology: A review. Front Endocrinol 2020;11:560375.

  • Galizzi G, Di Carlo M.Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration.Biology (Basel). 2022; 11:943.

  • De la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.Curr Alzheimer Res. 2012; 9(1):35-66.

  • Makki K, Froguel P, Wolowczuk I.Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. Int Sch Res Notices. 2013;139239.

  • Rhea EM, Banks WA, Raber J. Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites. Biomedicines. 2022; 10:1582.

  • Milstein JL, Ferris HA. The brain as an insulin-sensitive metabolic organ.Mol Metab. 2021; 52:101234.

  • Yoon JH, Hwang J, Son SU, Choi J, You S-W, Park H, et al. How can insulin resistance cause Alzheimer’s disease?Int J Mol Sci. 2023; 24:3506.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!